The mTOR inhibitor temsirolimus added to rituximab combined with dexamethasone, cytarabine, and cisplatinum (R-DHAP) for the treatment of patients with relapsed or refractory DLBCL: results from the Phase-II STORM Trial - Witzens-Harig, Mathias; Viardot, Andreas; Keller, Ulrich; Wosniok, Julia; Deuster, Oliver; Klemmer, Jennifer; Geueke, Anne-Marie; Meißner, Julia; Ho, Anthony Dick; Atta, Johannes; Marks, Reinhard; La Rosée, Paul; et al. (HemaSphere, 2021)
Gesehen am 24.11.2021